[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAF v600E or IDH1 Mutations

What is the purpose of the study? (in Layman's terms, please describe the study)

Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAF v600E or IDH1 Mutations

Upstate Institutional Review Board (IRB) Number:

1915915

Study/Protocol ID:

ACNS1931

Study Phase:

3

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

What is involved if I participate?

  • How long is the study?
    27 cycles
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    surgery, blood draws, lumbar punctures, imaging

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT0457617

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top